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Abstract
Background: No evidence of disease activity (NEDA; defined as no 12-week confirmed disability
progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-
enhancing lesions) using a fixed-study entry baseline is commonly used as a treatment outcome in
multiple sclerosis (MS).
Objective: The objective of this paper is to assess the effect of ocrelizumab on NEDA using re-
baselining analysis, and the predictive value of NEDA status.
Methods: NEDA was assessed in a modified intent-to-treat population (n¼ 1520) from the pooled
OPERA I and OPERA II studies over various epochs in patients with relapsing MS receiving ocreli-
zumab (600 mg) or interferon beta-1a (IFN b-1a; 44 lg).
Results: NEDA was increased with ocrelizumab vs IFN b-1a over 96 weeks by 75% (p< 0.001), from
Week 0–24 by 33% (p< 0.001) and from Week 24–96 by 72% (p< 0.001). Among patients with disease
activity during Weeks 0–24, 66.4% vs 24.3% achieved NEDA during Weeks 24–96 in the ocrelizumab
and IFN b-1a groups (relative increase: 177%; p< 0.001).
Conclusion: Superior efficacy with ocrelizumab compared with IFN b-1a was consistently seen in
maintaining NEDA status in all epochs evaluated. By contrast with IFN b-1a, the majority of patients
with disease activity early in the study subsequently attained NEDA status with ocrelizumab.
Keywords: NEDA, disease activity, relapse, disability progression, MRI activity
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Introduction
No evidence of disease activity (NEDA) is a compos-
ite measure of the absence of confirmed disability
worsening (as measured by the Expanded Disability
Status Scale (EDSS)) and of clinical and magnetic
resonance imaging (MRI) measures of disease activ-
ity in relapsing multiple sclerosis (RMS). NEDA was
originally described in a post-hoc analysis of the
placebo-controlled, two-year Phase III pivotal trial
for natalizumab.1 NEDA has since been widely
used in analyses of other disease-modifying therapies
(DMTs),2–9 and has been adopted as an outcome
measure in RMS clinical trials.10–13 NEDA may pro-
vide a more sensitive and comprehensive measure of
capturing overall treatment benefit and has been pro-
posed as a primary endpoint in future pivotal Phase III
clinical studies.14,15 NEDA is increasingly recog-
nized as an important treatment goal for patients
with RMS16 and has been shown to be informative
in the prediction of long-term disability progression
both independent of DMT type17 (cohort study) and
in the core and extension periods of clinical trial
patient populations.18
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As a binary outcome, NEDA status and its failure are
often driven by MRI components of the measure and
hence are particularly influenced by the frequency of
MRI assessments.8,14 The analysis of NEDA is also
affected by the pharmacodynamics of the particular
therapy assessed. Re-baselining, wherein a post-
study baseline time point is utilized as the new
baseline reference for subsequent assessment of dis-
ability worsening and disease activity, therefore may
reflect a truer representation of a DMT’s steady state
of efficacy16 unconfounded by any initial disease
activity carried over from baseline and recent pre-
baseline disease state.
B cells are a significant contributor to the pathogen-
esis of MS.19,20 CD20 is a cell-surface antigen
expressed on pre-B cells, mature B cells and
memory B cells, but not lymphoid stem cells and
plasma cells.21–23 Ocrelizumab is a recombinant,
humanized monoclonal antibody that selectively
depletes CD20-expressing B cells24,25 while preserv-
ing the capacity for B-cell reconstitution and main-
taining pre-existing humoral immunity.26,27 In the
two identical Phase III trials, OPERA I and
OPERA II, ocrelizumab significantly reduced all
individual components of NEDA compared with
high-dose, high-frequency interferon beta-1a (IFN
b-1a) at Week 96 in patients with RMS.28 The objec-
tive of the current analyses was to assess the effect
of ocrelizumab on the proportion of patients with
NEDA and determine the predictive value of
NEDA over time in multiple epochs across the
pooled OPERA I and OPERA II studies.
Patients and methods
Trial design and patients
NEDA was determined in the pooled population of
the two identical Phase III, multicenter, randomized,
double-blind, double-dummy, parallel-group OPERA
I and OPERA II trials (OPERA I/NCT01247324 and
OPERA II/NCT01412333). The study protocol was
approved by each center’s independent ethics com-
mittee. The study design was written in accordance
with the Declaration of Helsinki and Good Clinical
Practice guidelines, and all enrolled patients provided
written informed consent. The OPERA I and OPERA
II trials were deemed poolable based on their identical
protocols and according to formal poolability testing
results.28 Baseline demographics and disease charac-
teristics were not different within each study arm or
between studies. Study details have been reported
previously.28 Key eligibility criteria included an age
of 18 to 55 years, diagnosis of RMS (2010 revised
McDonald criteria)29 and an EDSS score of 0 to 5.5 at
screening. Patients were randomized (1:1) to receive
either ocrelizumab 600 mg by intravenous infusion
every 24 weeks or subcutaneous IFN b-1a three
times per week at a dose of 44 lg throughout the
96-week treatment period (including a per-label incre-
mental titration scheme in the first four weeks).
Patients were stratified by region (United States
(US) vs rest of world (ROW)) and baseline EDSS
score (<4.0 and 4.0) in the randomization for
OPERA I and OPERA II.
Clinical and MRI endpoints, including NEDA
EDSS scores were determined at screening, baseline
and every 12 weeks: Confirmed disability progres-
sion (CDP) was defined as a 1-point increase in
EDSS score from a baseline EDSS score of 0–5.5, or
a 0.5-point increase in EDSS score from a baseline
EDSS score greater than 5.5, sustained for at least
12 weeks (12-week CDP). Protocol-defined relapses
were new or worsening neurological symptoms
attributable to MS: Symptoms must (i) persist for
greater than 24 hours, should not be attributable to
confounding clinical factors, and be immediately
preceded by a stable or improving neurological
state for at least 30 days; and (ii) be accompanied
by objective neurological worsening consistent with
an increase of at least half a step on the EDSS scale,
or two points on at least one of the appropriate
Functional Systems Scores (FSSs), or one point on
two or more of the appropriate FSSs. Brain MRI was
performed at baseline and Weeks 24, 48 and 96; new
or enlarging T2 lesions and/or T1 gadolinium-
enhancing lesions on any scan during the epoch
investigated were considered evidence of MRI
disease activity. NEDA status was defined as the
combined absence of: protocol-defined relapses;
12-week CDP; new or enlarging T2 lesions; and
T1 gadolinium-enhancing lesions.
Statistical analyses
NEDA outcome was primarily assessed in a modi-
fied intent-to-treat (mITT) population over the con-
trolled treatment phase (baseline to 96 weeks),28
which included all patients in the intent-to-treat pop-
ulation, but patients who discontinued treatment
early for reasons other than lack of efficacy or
death and had NEDA before early discontinuation
were excluded. Further analyses evaluated the pro-
portion of patients with NEDA for several epochs,
including: Weeks 0–48; Weeks 48–96 (where all
components of NEDA including 12-week CDP
were re-baselined to Week 48); Weeks 0–24;
Weeks 24–48 (where all components of NEDA
including 12-week CDP were re-baselined to Week
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24); and Weeks 24–96 (where all components of
NEDA including 12-week CDP were re-baselined
to Week 24). NEDA and its components were com-
pared in patients treated with ocrelizumab with those
receiving IFN b-1a in a post-hoc analysis using the
Cochran–Mantel–Haenszel test stratified by study,
geographic region (US vs ROW) and baseline
EDSS score (<4.0 vs 4.0). Patients who discontin-
ued treatment early with at least one event (i.e.
protocol-defined relapse, 12-week CDP, new or
enlarging T2 lesion or T1 gadolinium-enhancing
lesion) before early discontinuation were considered
as having evidence of disease activity (EDA). Even
if a patient did not report an event before early dis-
continuation, the patient was considered as having
EDA if the reason for early discontinuation was lack
of efficacy or death.
Probability of attaining or maintaining NEDA
relative to earlier EDA or NEDA status, and the
predictive value of NEDA status
Subgroups of patients by NEDA status in Weeks
0–24 were assessed for subsequent NEDA status in
Weeks 24–96 and in Weeks 24–48. Similarly, sub-
groups of patients by NEDA status in Weeks 24–48
were assessed for subsequent NEDA status in Weeks
48–96. Using the pooled treatment arms, NEDA
status in Weeks 0–48 was used to predict time to
(i) first protocol-defined relapse, and (ii) first
12-week and 24-week CDP in Weeks 48–96, and
was evaluated based on the Cox proportional
hazard regression model which included the NEDA
during Weeks 0–48 as a factor, stratified by study,
geographical region (US vs ROW) and baseline
EDSS score (<4.0 vs 4.0).
Results
Patient demographics and disease characteristics
In the OPERA I and OPERA II trials, the pooled
intention-to-treat population comprised 1656
patients (IFN b-1a, n¼ 829; ocrelizumab, n¼ 827).
The mITT reference population used for the NEDA
analysis comprised 759 and 761 patients randomized
to high-dose, high-frequency IFN b-1a and ocrelizu-
mab, respectively. Detailed baseline demographics
and disease characteristics of (i) the mITT popula-
tion and (ii) patients with EDA and NEDA over 96
weeks are presented by treatment arm in Table 1. All
major baseline covariates were balanced between
treatment groups in the mITT population.
Compared with patients who maintained NEDA
over 96 weeks, patients with EDA across treatment
groups had slightly more relapses recorded in the 12
months prior to baseline, a greater number of T1
gadolinium-enhanced lesions and a higher T2
lesion burden at baseline. The age and proportion
of female patients were slightly lower in the
EDA group. Baseline EDSS score, disease duration
and normalized brain volume were similar between
patients who maintained NEDA or experienced EDA
events.
Overall NEDA (Week 0–96) and re-baselined NEDA
(Weeks 24–96) status in the pooled OPERA I and
OPERA II studies
In the pooled analyses of OPERA I and OPERA II,
the relative proportion of patients with NEDA was
increased by 75% (47.7% vs 27.1%; p< 0.001)
with ocrelizumab compared with IFN b-1a over 96
weeks (Figure 1(a)).28 Following re-baselining at
Week 24, the relative proportion of patients with
NEDA was 72% higher (72.2% vs 41.9%;
p< 0.001) with ocrelizumab compared with IFN
b-1a during Weeks 24–96 (Figure 1(b)).
During the 96-week epoch, a significant difference
in the proportion of patients without disease activity
was seen for each individual component of NEDA,
including 12-week CDP, with ocrelizumab com-
pared with IFN b-1a (p< 0.001; Table 2). This
was reflected in the proportion of patients with no
disability worsening and clinical disease activity (no
12-week CDP and no relapses: ocrelizumab 73.8%
vs IFN b-1a 59.4%; p< 0.001) and no brain MRI
measures of disease activity (no new or enlarging T2
lesions and no T1 gadolinium-enhancing lesions:
ocrelizumab 62.2% vs IFN b-1a 37.6%; p< 0.001;
Table 2). Following re-baselining at Week 24,
similar results were seen during Weeks 24–96 for
the individual components of NEDA and the pair-
wise combination of clinical and MRI measures
(Table 2).
NEDA status analysis in all epochs of OPERA
studies
Irrespective of the various epochs studied, a favor-
able outcome was seen with ocrelizumab compared
with IFN b-1a; the relative proportion of patients
with NEDA was 56% higher (54.6% vs 34.9%)
with ocrelizumab during Weeks 0–48, 43% higher
(81.8% vs 57.3%) during Weeks 48–96, 33%
higher (60.8% vs 45.7%) during Weeks 0–24 and
45% higher (85.8% vs 59.0%) during Weeks 24–48
(all comparisons p< 0.001; Table 2). Sensitivity
analyses of the relative proportion of patients with
NEDA during Weeks 0–48 excluding T1
gadolinium-enhancing lesions at Week 24 revealed
Havrdova´ et al.
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Table 1. Patient baseline demographics and disease characteristics of the total pooled mITT patient population, and of patients
maintaining NEDA vs having EDA over 96 weeks.
Baseline demographics and
disease characteristics
Pooled mITT population Patients with NEDA Patients with EDA
IFN b-1a
N¼ 759
Ocrelizumab
N¼ 761
IFN b-1a
N¼ 206
Ocrelizumab
N¼ 363
IFN b-1a
N¼ 553
Ocrelizumab
N¼ 398
Age, mean (SD), years 37.1 (9.2) 37.2 (9.1) 39.4 (9.3) 38.4 (9.0) 36.2 (9.0) 36.1 (9.1)
Female, % (n) 66.8 (507) 64.8 (493) 72.8 (150) 67.5 (245) 64.6 (357) 62.3 (248)
Time since MS symptom
onset, mean (SD), years
6.4 (6.1) 6.6 (6.1) 6.1 (6.1) 6.8 (6.3) 6.5 (6.1) 6.4 (5.9)
Time since MS diagnosis,
mean (SD), years
3.9 (4.8) 3.9 (4.9) 3.5 (4.8) 4.1 (5.1) 4.0 (4.9) 3.8 (4.6)
Number of relapses in previ-
ous 12 months, mean (SD)
1.3 (0.7)a 1.3 (0.7) 1.3 (0.6) 1.3 (0.6) 1.4 (0.7)b 1.4 (0.7)
EDSS score, mean (SD) 2.8 (1.3) 2.8 (1.3) 2.8 (1.3) 2.7 (1.2) 2.8 (1.3) 2.9 (1.3)
MRI
Number of T1 Gdþ lesions,
mean (SD)
2.0 (5.2)c 1.8 (4.7)d 0.4 (1.4)e 0.7 (1.8)f 2.6 (5.9)g 2.8 (6.1)h
Brain T2 hyperintense
lesion volume,
median (range), cm3
6.2 (0–76.1)i 5.4 (0–96.0)j 3.8 (0–60.2)k 3.8 (0–96.0)l 7.2 (0.1–76.1)m 7.5 (0–83.2)n
Normalized brain volume,
mean (SD), cm3
1499.8 (88.3)o 1501.7 (88.1)p 1502.3 (84.1)q 1502.3 (90.3)r 1498.9 (89.8)s 1501.3 (86.2)t
EDA: evidence of disease activity; EDSS: Expanded Disability Status Scale; Gdþ: gadolinium-enhancing; IFN b-1a: interferon beta-1a; mITT:
modified intent-to-treat; MRI: magnetic resonance imaging; MS: multiple sclerosis; NEDA: no evidence of disease activity; SD: standard
deviation.
an¼ 757; bn¼ 551; cn¼ 752; dn¼ 753; en¼ 205; fn¼ 357; gn¼ 547; hn¼ 396; in¼ 754; jn¼ 756; kn¼ 205; ln¼ 359; mn¼549; nn¼ 397;
on¼ 749; pn¼ 754; qn¼ 204; rn¼ 357; sn¼ 545; tn¼ 397.
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Figure 1. Proportion of patients with NEDA during (a) Weeks 0–96, and (b) during Weeks 24–96, re-baselined to
Week 24.
Compared using the Cochran–Mantel–Haenszel test stratified by study, geographic region (United States vs rest of world)
and baseline EDSS score (<4.0 vs 4.0). Weeks 24–96: MRI at Week 48, Week 96 and unscheduled post-Week 24 scans
prior to Week 96 are used in the definition of NEDA; this implies that analysis of the Week 24–96 epoch is based on two
MRI scans. Weeks 24–96: Data were re-baselined to Week 24, i.e. all components of NEDA including 12-week CDP are
defined relative to Week 24.
CDP: confirmed disability progression; EDSS: Expanded Disability Status Scale; IFN b-1a: interferon beta-1a; MRI:
magnetic resonance imaging; NEDA: no evidence of disease activity.
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similar results to the original analysis
(Supplementary Materials Table S1).
Probability of attaining or maintaining NEDA
relative to earlier EDA or NEDA status
In the ocrelizumab and IFN b-1a groups
respectively, 66.4% vs 24.3% of patients with
EDA during Weeks 0–24 subsequently attained
NEDA status during Weeks 24–96 (relative increase
with ocrelizumab: 177%; p< 0.001, Figure 2(a)),
and 82.8% vs 44.0% attained NEDA status during
Weeks 24–48 (relative increase: 88%; p< 0.001,
Figure 2(b)). Among patients with NEDA during
Weeks 0–24, the proportion of patients who main-
tained NEDA during Weeks 24–96 was 75.9% vs
61.5% in the ocrelizumab and IFN b-1a groups,
respectively (relative increase with ocrelizumab:
23%; p< 0.001), and during Weeks 24–48 the pro-
portion was 87.6% vs 75.7% (relative increase with
ocrelizumab: 16%; p< 0.001). Of patients with
EDA during Weeks 24–48, in the ocrelizumab and
IFN b-1a groups respectively, 77.2% vs 38.3% sub-
sequently attained NEDA status during Weeks
48–96 (relative increase with ocrelizumab: 106%;
p< 0.001, Figure 2(c)); among those patients with
NEDA during Weeks 24–48, the proportion
of patients who maintained NEDA during Weeks
48–96 was 82.5% vs 69.9% (relative increase with
ocrelizumab: 18%; p< 0.001).
Predictive value of first-year NEDA status for sub-
sequent risk of relapse and disability progression
When the treatment arms were pooled, patients with
NEDA during Weeks 0–48 had a subsequent (Weeks
48–96) 53% risk reduction (hazard ratio (HR): 0.47;
95% confidence interval (CI): 0.35–0.65; p< 0.001)
in time to first relapse, a 36% risk reduction (HR:
0.64; 95% CI: 0.44–0.94; p¼ 0.023) in time to first
12-week CDP, and a 39% risk reduction (HR: 0.61;
95% CI: 0.39–0.95; p¼ 0.028) in time to first
24-week CDP, compared with those patients with
EDA during Weeks 0–48.
Discussion
A higher proportion of patients had NEDA with
ocrelizumab at the first MRI at Week 24 and in all
epochs of the OPERA studies compared with high-
dose, high-frequency IFN b-1a. Over two years,
48% of patients treated with ocrelizumab had
NEDA, and as many as 72% had NEDA in Weeks
24–96 and 82% in Weeks 48–96, which is greater
than that observed with other high-efficacy therapies
in similar epochs.1,30,31 Absolute proportions of
patients maintaining NEDA status should be consid-
ered in the context of the existence of a certain
level of inherent background noise in the binary
assessment of NEDA status because of potential
false-positive detection of clinical EDA events, par-
ticularly for relapses, which may yield a treatment
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Figure 2. Proportion of patients with NEDA during (a) Weeks 24–96, (b) Weeks 24–48 among patients with EDA in Weeks 0–24 and (c) Weeks
48–96 among patients with EDA in Weeks 24–48.
All components of NEDA including 12-week CDP are defined relative to Week 24 (a) and (b), and relative to Week 48 (c). Comparison using the
Cochran–Mantel–Haenszel test stratified by study, geographic region (United States vs rest of world) and baseline EDSS score (<4.0 vs 4.0).
CDP: confirmed disability progression; EDA: evidence of disease activity; EDSS: Expanded Disability Status Scale; IFN b-1a: interferon beta-1a;
MRI: magnetic resonance imaging; NEDA: no evidence of disease activity; EDA: evidence of disease activity.
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ceiling effect. Pairwise combinations of disease
parameters in the clinical and MRI components of
NEDA showed the consistent overall benefit of ocre-
lizumab compared with IFN b-1a, which was further
reflected in all the individual components of NEDA,
including confirmed disability progression.
Compared with patients who maintained NEDA
over 96 weeks, the patients with EDA across treat-
ment groups had higher brain MRI activity at base-
line as measured by T1 gadolinium-enhancing
lesions and higher T2 lesion burden, while no sizable
difference was seen in pre-baseline relapse rate, and
baseline EDSS score, disease duration and brain
atrophy.
The early impact of ocrelizumab on MS disease
activity was shown in a Phase II, randomized,
placebo-controlled, double-blind trial in patients
with relapsing–remitting MS, in which ocrelizumab
demonstrated a robust effect on MRI activity as
early as Week 8 after initiating treatment.32
However, in order to represent the full efficacy of
a DMT unconfounded by disease activity carried
over during the first four to eight weeks from treat-
ment initiation, particularly MRI related, a re-
baselining approach at first available MRI has been
suggested.3,14,33,34 Re-baselining MS disease param-
eters to Week 24 showed a 72% relative increase in
the proportion of ocrelizumab-treated patients with
NEDA from Weeks 24 to 96 compared with IFN
b-1a-treated patients. Moving into the clinical prac-
tice setting, the optimal timing of re-baselining
should reflect the anticipated timing for reaching
complete DMT efficacy, to give a more reliable indi-
cation of subsequent drug failure. Conclusions from
cross-trial comparisons are limited because of differ-
ences including comparators, patient populations,
MRI techniques, frequency of assessments, analysis
methods and definitions of NEDA. Nevertheless,
irrespective of the epoch chosen (including base-
line–Week 24, baseline–Week 48 and Weeks 24–
96), greater absolute proportions of patients with
NEDA were observed in the present analysis com-
pared with those reported with other high-efficacy
therapies for RMS.1,8,10,33
As noted above and reported in other studies,14,35 the
lower frequency of MRI scans during Weeks 48–96
compared with the other epochs described may have
influenced the proportions of patients maintaining
NEDA. However, despite the longer duration and
the additional (Week 48) scan within the NEDA
analysis of the Week 24–96 epoch, the proportion
of patients maintaining NEDA in the ocrelizumab
group was higher (72%) from Weeks 24–96 than
from Weeks 0–24 (61%), while the reverse was
seen in the IFN b-1a group.
The majority of patients with EDA in Weeks 0–24 or
Weeks 24–48 subsequently attained NEDA in
Weeks 24–96 and Weeks 48–96 with ocrelizumab
treatment, whereas such patients mainly continued to
experience disease activity with IFN b-1a. Delayed
conversion to NEDA status in patients with EDA
in the first few months of treatment has been
similarly reported for other high-efficacy
DMTs,1,31,33 findings that argue against the immedi-
ate discontinuation of such therapies based on early
signs of EDA, although longer-term confirmation of
maintenance of NEDA beyond Week 96 warrants
further investigation in the open-label extension
study.
When pooling treatment arms, NEDA status in the
first year (Weeks 0–48) predicted a lower risk of
relapse (Kaplan–Meier analysis of time to first
relapse) and a lower risk of disability progression
(as measured by 12- and 24-week CDP) in the
second year (Weeks 48–96). The lower risk of sub-
sequent relapse and disability worsening in patients
with NEDA during the first year, combined with the
high proportion of patients receiving ocrelizumab
treatment maintaining NEDA in Year 2 in those
patients with NEDA in Year 1, suggest NEDA
status over the short term may predict longer-term
benefits. Contradictory data have been reported on
the prognostic value of NEDA status over two years
in predicting future disability progression up to 10
years, at least in patient cohorts from real-world set-
tings where the majority of patients were treated
with self-injectable DMTs (interferons or glatiramer
acetate).17,36,37 Few patients maintained NEDA over
the long term in studies in which self-injectable
DMTs were used (7.9% over seven years;17 0%
over 10 years9). Conversely, NEDA was enhanced
in patients over the long term in studies in which
more effective DMTs were used (34% over seven
years with natalizumab;38 40% over five years with
alemtuzumab39). These data support the notion that,
balanced with any risk associated with a particular
DMT, NEDA may be a realizable long-term treat-
ment goal for patients with RMS in the era of higher-
efficacy therapies. Furthermore, re-baselining of
NEDA status especially during the first year of
DMT initiation might have value in clinical practice
to assess early treatment response, and inform
longer-term therapeutic decisions to optimize the
control of MS disease activity.
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Further evolution of the NEDA concept may include
the future integration of brain volume loss, and
research is ongoing to determine the optimal thresh-
old(s) of annualized rates that may discriminate
pathological atrophy at the individual patient level,
while accounting for the effect of aging.9,40
Similarly, the incorporation of cognitive, ambulation
and upper extremity function measures may enable a
more comprehensive ascertainment of the absence of
disability progression when assessing NEDA.
Overall, ocrelizumab consistently resulted in a pro-
found reduction of clinical and subclinical disease
activity compared with IFN b-1a in patients with
RMS, as measured by NEDA across various
epochs. Understanding the associations between
NEDA and patient-reported outcomes is warranted
to better inform the day-to-day relevance of main-
taining NEDA status. Data from open-label exten-
sion studies will help determine whether NEDA
maintained in the two-year OPERA studies will
translate into sustained NEDA and enhanced protec-
tion against accrual of disability over the long term.
Trial registration
ClinicalTrials.gov identifiers:
OPERA I/NCT01247324 and
OPERA II/NCT01412333.
https://clinicaltrials.gov/ct2/show/NCT01247324
https://clinicaltrials.gov/ct2/show/NCT01412333
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